349: BIO's John Crowley on RFK Jr. and tariffs, plus calls for more federal biotech funding
John Crowley, the CEO of industry lobbying group BIO, joins us to discuss the layoffs at the Food and Drug Administration, RFK Jr.'s comments on Novavax's Covid-19 vaccine, and how the trade group is ...
10 Apr 202540min
348: Cuts, ousters and drama at the FDA
STAT’s FDA reporter Lizzy Lawrence joins to discuss her inside-the-agency reporting on how Robert F. Kennedy Jr. forced top FDA officials to resign at a time when newly sworn-in FDA Commissioner Makar...
3 Apr 202531min
347: More HHS upheaval, 23andMe's bankruptcy, and AI for cancer survival
Adam, Elaine, and Allison discuss the Trump administration’s plan for huge job cuts and a restructuring of the country’s top health care agencies, the approval of the first drug to treat a devastating...
27 Mar 202531min
346: Zealand's obesity strategy and Immunovant's curious development plan
We chat about positive data from Immunovant's autoimmune drug candidate, a patient death linked to Sarepta's gene therapy, and dispatches from our STAT Breakthrough Summit East in New York. We also br...
20 Mar 202542min
345: The sudden withdrawal of a CDC nominee and what went wrong with Covid policies
We bring on our colleague Sarah Owermohle to discuss the White House's sudden move to withdraw the nomination of Dave Weldon as its pick to run the CDC just hours before Weldon's confirmation hearing....
13 Mar 202531min
344: Trump's FDA commissioner nominee takes the hot seat
Will Marty Makary be confirmed as the next commissioner of the Food and Drug Administration? Will he bring back employees laid off by DOGE? And what did he get wrong during his confirmation hearing? W...
6 Mar 202525min
343: Turbulence at the FDA, Bluebird Bio's sale and young biotech VCs
It’s a STAT reporter two-fer guest episode. First, Lizzy Lawrence joins from D.C. to dish on the upheaval and drama taking place at the FDA. Then, we chat with Jason Mast about Bluebird Bio, its fire ...
27 Feb 202532min
342: FDA cuts, zombie biotechs, and too much weight loss?
Mizuho analyst Jared Holz joins to discuss Adam's column on biotech's dark period. We also talk about Elaine's latest article on the push for greater and greater weight loss from obesity drugs, along ...
20 Feb 202541min
